EDIT
Editas Medicine, Inc. NASDAQ Listed Feb 3, 2016$3.03
After hrs
$2.85
-1.72%
Mkt Cap $296.6M
52w Low $1.29
53.6% of range
52w High $4.54
50d MA $2.68
200d MA $2.65
P/E (TTM)
-1.6x
EV/EBITDA
-0.8x
P/B
9.4x
Debt/Equity
2.8x
ROE
-586.6%
P/FCF
-1.1x
RSI (14)
—
ATR (14)
—
Beta
2.04
50d MA
$2.68
200d MA
$2.65
Avg Volume
1.7M
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
11 Hurley Street · Cambridge, MA 02141 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.27 | -0.06 | +77.8% | 2.32 | +3.9% | +13.8% | +0.8% | -4.5% | -3.9% | +4.1% | — |
| Nov 10, 2025 | AMC | -0.38 | -0.28 | +26.3% | 2.52 | +2.8% | +5.6% | +1.5% | -5.9% | +2.4% | -0.8% | — |
| Aug 12, 2025 | AMC | -0.41 | -0.63 | -53.7% | 2.29 | +7.0% | +34.5% | -3.9% | +2.4% | -9.9% | -3.7% | — |
| May 12, 2025 | AMC | -0.51 | -0.43 | +15.7% | 1.54 | +0.6% | -2.6% | -8.0% | +1.4% | +7.9% | -1.3% | — |
| Mar 5, 2025 | AMC | -0.39 | -0.55 | -41.0% | 2.05 | -5.9% | -13.2% | -3.4% | -9.3% | -5.8% | +2.7% | — |
| Nov 4, 2024 | AMC | -0.76 | -0.75 | +1.3% | 2.88 | -0.7% | +8.3% | +5.1% | -3.4% | -1.6% | +5.8% | — |
| Aug 7, 2024 | AMC | -0.69 | -0.82 | -18.8% | 4.11 | +6.3% | +2.4% | -5.7% | -1.3% | +1.8% | -6.3% | — |
| May 8, 2024 | AMC | -0.63 | -0.76 | -20.6% | 5.04 | +3.0% | +10.3% | -4.3% | +7.3% | -0.5% | +5.6% | — |
| Feb 28, 2024 | AMC | -0.52 | -0.23 | +55.8% | 11.07 | +2.0% | -9.1% | +4.7% | -5.8% | -7.9% | -0.7% | — |
| Nov 3, 2023 | AMC | -0.64 | -0.55 | +14.1% | 8.31 | +1.9% | +0.0% | +7.8% | -6.2% | -6.3% | -2.5% | — |
| Aug 2, 2023 | AMC | -0.76 | -0.56 | +26.3% | 9.14 | +0.0% | +1.9% | -2.8% | -6.9% | +5.6% | -0.7% | — |
| May 5, 2023 | AMC | -0.79 | -0.71 | +10.1% | 9.77 | -0.1% | -1.5% | +6.8% | -2.8% | -4.3% | +0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10 | Jones Trading | Upgrade | Hold → Buy | — | $2.32 | $2.41 | +3.9% | +13.8% | +0.8% | -4.5% | -3.9% | +4.1% |
| Mar 9 | Chardan Capital | Maintains | Buy → Buy | — | $2.00 | $1.98 | -1.0% | +16.0% | +13.8% | +0.8% | -4.5% | -3.9% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.52 | $2.55 | +1.2% | +9.5% | +1.1% | -1.1% | -7.2% | +5.9% |
| Sep 3 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $2.47 | $2.53 | +2.4% | +1.2% | +0.8% | +9.5% | +1.1% | -1.1% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.96 | $3.05 | +3.0% | +2.4% | -9.9% | -3.7% | +1.5% | +2.2% |
| Aug 13 | Baird | Maintains | Outperform → Outperform | — | $2.29 | $2.45 | +7.0% | +34.5% | -3.9% | +2.4% | -9.9% | -3.7% |
| May 13 | Baird | Maintains | Outperform → Outperform | — | $1.54 | $1.55 | +0.6% | -2.6% | -8.0% | +1.4% | +7.9% | -1.3% |
| Dec 16 | JP Morgan | Downgrade | Neutral → Underweight | — | $1.44 | $1.44 | +0.0% | +2.8% | +2.7% | -11.2% | -0.7% | -2.2% |
| Dec 16 | Evercore ISI | Maintains | Outperform → Outperform | — | $1.44 | $1.44 | +0.0% | +2.8% | +2.7% | -11.2% | -0.7% | -2.2% |
| Dec 13 | Baird | Maintains | Outperform → Outperform | — | $1.89 | $1.75 | -7.4% | -23.8% | +2.8% | +2.7% | -11.2% | -0.7% |
| Dec 13 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $1.89 | $1.75 | -7.4% | -23.8% | +2.8% | +2.7% | -11.2% | -0.7% |
| Dec 13 | Barclays | Maintains | Equal Weight → Equal Weight | — | $1.89 | $1.75 | -7.4% | -23.8% | +2.8% | +2.7% | -11.2% | -0.7% |
| Dec 13 | Chardan Capital | Downgrade | Buy → Neutral | — | $1.89 | $1.75 | -7.4% | -23.8% | +2.8% | +2.7% | -11.2% | -0.7% |
| Dec 13 | Stifel | Downgrade | Buy → Hold | — | $1.89 | $1.75 | -7.4% | -23.8% | +2.8% | +2.7% | -11.2% | -0.7% |
| Dec 11 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $2.10 | $2.09 | -0.5% | -5.2% | -5.0% | -23.8% | +2.8% | +2.7% |
| Nov 5 | Chardan Capital | Maintains | Buy → Buy | — | $2.88 | $2.86 | -0.7% | +8.3% | +5.1% | -3.4% | -1.6% | +5.8% |
| Nov 5 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $2.88 | $2.86 | -0.7% | +8.3% | +5.1% | -3.4% | -1.6% | +5.8% |
| Nov 5 | Stifel | Maintains | Buy → Buy | — | $2.88 | $2.86 | -0.7% | +8.3% | +5.1% | -3.4% | -1.6% | +5.8% |
| Nov 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $2.88 | $2.86 | -0.7% | +8.3% | +5.1% | -3.4% | -1.6% | +5.8% |
| Nov 5 | Truist | Maintains | Buy → Buy | — | $2.88 | $2.86 | -0.7% | +8.3% | +5.1% | -3.4% | -1.6% | +5.8% |
| Nov 5 | Barclays | Maintains | Equal Weight → Equal Weight | — | $2.88 | $2.86 | -0.7% | +8.3% | +5.1% | -3.4% | -1.6% | +5.8% |
| Oct 23 | Wells Fargo | Maintains | Overweight → Overweight | — | $3.29 | $3.28 | -0.3% | -2.4% | -0.9% | +0.0% | +2.5% | -4.6% |
| Oct 23 | Evercore ISI | Maintains | In Line → In Line | — | $3.29 | $3.28 | -0.3% | -2.4% | -0.9% | +0.0% | +2.5% | -4.6% |
| Oct 22 | Chardan Capital | Maintains | Buy → Buy | — | $3.76 | $3.75 | -0.3% | -12.5% | -2.4% | -0.9% | +0.0% | +2.5% |
| Sep 19 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $3.88 | $4.01 | +3.4% | +0.8% | -3.6% | -2.9% | -3.6% | -4.0% |
| Aug 8 | BofA Securities | Upgrade | Neutral → Buy | — | $4.11 | $4.37 | +6.3% | +2.4% | -5.7% | -1.3% | +1.8% | -6.3% |
| Aug 8 | Truist | Maintains | Buy → Buy | — | $4.11 | $4.37 | +6.3% | +2.4% | -5.7% | -1.3% | +1.8% | -6.3% |
| Aug 8 | Barclays | Maintains | Equal Weight → Equal Weight | — | $4.11 | $4.37 | +6.3% | +2.4% | -5.7% | -1.3% | +1.8% | -6.3% |
| Jun 18 | Oppenheimer | Maintains | Perform → Perform | — | $5.07 | $5.29 | +4.3% | -0.6% | +0.0% | +1.4% | -0.6% | -2.2% |
| May 30 | Evercore ISI | Maintains | In Line → In Line | — | $5.10 | $5.15 | +1.0% | +1.4% | +0.6% | +4.0% | +6.3% | -2.6% |
| May 9 | Morgan Stanley | Upgrade | Underweight → Equal Weight | — | $5.04 | $5.19 | +3.0% | +10.3% | -4.3% | +7.3% | -0.5% | +5.6% |
| May 9 | Citigroup | Maintains | Buy → Buy | — | $5.04 | $5.19 | +3.0% | +10.3% | -4.3% | +7.3% | -0.5% | +5.6% |
| May 9 | Barclays | Maintains | Equal Weight → Equal Weight | — | $5.04 | $5.19 | +3.0% | +10.3% | -4.3% | +7.3% | -0.5% | +5.6% |
| Feb 29 | Citigroup | Maintains | Buy → Buy | — | $11.07 | $11.29 | +2.0% | -9.1% | +4.7% | -5.8% | -7.9% | -0.7% |
| Feb 29 | Barclays | Maintains | Equal Weight → Equal Weight | — | $11.07 | $11.29 | +2.0% | -9.1% | +4.7% | -5.8% | -7.9% | -0.7% |
| Feb 27 | JP Morgan | Maintains | Neutral → Neutral | — | $8.06 | $8.30 | +3.0% | +9.9% | +24.9% | -9.1% | +4.7% | -5.8% |
| Dec 12 | Truist | Maintains | Buy → Buy | — | $9.91 | $10.00 | +0.9% | -0.7% | +5.7% | +4.2% | +0.8% | -4.0% |
| Oct 24 | Citigroup | Upgrade | Neutral → Buy | — | $6.25 | $6.64 | +6.2% | +5.1% | +0.8% | -1.7% | -3.8% | +1.1% |
| Oct 18 | JP Morgan | Upgrade | Underweight → Neutral | — | $6.81 | $6.86 | +0.7% | -3.1% | -2.6% | -2.2% | -0.6% | +5.1% |
| Oct 17 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $7.26 | $6.97 | -4.0% | -6.2% | -3.1% | -2.6% | -2.2% | -0.6% |
| Sep 29 | Stifel | Upgrade | Hold → Buy | — | $6.92 | $7.83 | +13.2% | +12.7% | -8.5% | +2.7% | -3.8% | +1.7% |
| Sep 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.00 | $9.06 | +0.7% | -5.9% | -0.8% | -0.1% | -4.5% | -0.2% |
| Aug 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.02 | $8.99 | -0.3% | +0.4% | -0.2% | -1.4% | +1.9% | -2.8% |
| Aug 3 | Oppenheimer | Maintains | Perform → Perform | — | $9.14 | $9.14 | +0.0% | +1.9% | -2.8% | -6.9% | +5.6% | -0.7% |
| Aug 3 | Chardan Capital | Maintains | Buy → Buy | — | $9.14 | $9.14 | +0.0% | +1.9% | -2.8% | -6.9% | +5.6% | -0.7% |
| Jun 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.93 | $9.60 | -3.3% | +15.5% | -3.3% | -16.3% | -5.0% | -5.2% |
| Jun 13 | Raymond James | Upgrade | Market Perform → Outperform | — | $9.93 | $9.60 | -3.3% | +15.5% | -3.3% | -16.3% | -5.0% | -5.2% |
| May 9 | Oppenheimer | Maintains | Perform → Perform | — | $9.62 | $9.51 | -1.1% | +6.8% | -2.8% | -4.3% | +0.2% | +4.5% |
| May 8 | Chardan Capital | Maintains | Buy → Buy | — | $9.77 | $9.76 | -0.1% | -1.5% | +6.8% | -2.8% | -4.3% | +0.2% |
| May 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $9.77 | $9.76 | -0.1% | -1.5% | +6.8% | -2.8% | -4.3% | +0.2% |
No insider trades available.
8-K · 2.02
!! High
Editas Medicine, Inc. -- 8-K 2.02: Earnings Results
Editas Medicine (EDIT) released quarterly earnings results, with the full financial details available in the accompanying press release exhibit.
May 5
8-K · 4.01
!!! Very High
Unknown — 8-K 4.01: Auditor Change / Resignation
EDIT's auditor change to Ernst & Young signals potential accounting disputes or internal control concerns, warranting investor scrutiny of the resignation letter and reasons behind the switch.
Apr 7
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
EDIT's CRISPR patent dispute with CVC remains unresolved as CVC signals intent to appeal, creating ongoing litigation uncertainty that could affect the company's core gene-editing technology licensing value and investor confidence.
Mar 27
8-K
Editas Medicine, Inc. -- 8-K Filing
Editas Medicine's lead gene-editing candidate EDIT-401 remains on track for mid-2026 IND submission with first-in-human trial initiation planned, supported by cash runway extending into Q3 2027.
Mar 9
Data updated apr 25, 2026 6:26am
· Source: massive.com